retatrutide approval status 2025 Retatrutide vs. Tirzepatide: Dual vs. Triple Action, Doses, Benefits, Side Effects Demand for Unapproved Weight-Loss Drug

For its second application, the FDA set a PDUFA date of May 14, 2024, but this was pushed back by three months after Ascendis filed a major amendment to the application

Many patients taking GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) report feeling unusually cold during treatment

Improved diabetes control is also associated with lower recurrence risk

However, oral semaglutide still provides substantial and clinically meaningful weight loss

These weight-related health conditions can lead to a wide range of issues that become difficult to manage on a daily basis and can even become life-threatening, so reducing the risks of developing these health conditions in an effective way is incredibly important for those undergoing medical weight loss treatments

Contacting the Centra Internal Medicine team is the best way to get the most accurate pricing and find an option that suits your weight loss needs and budget